Amalia Gastaldelli

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8423215/publications.pdf

Version: 2024-02-01

407 papers	29,376 citations	5574 82 h-index	5988 160 g-index
419 all docs	419 docs citations	419 times ranked	27697 citing authors

#	Article	IF	Citations
1	An extra virgin olive oilâ€enriched chocolate spread positively modulates insulinâ€resistance markers compared with a palm oilâ€enriched one in healthy young adults: A doubleâ€blind, crossâ€over, randomised controlled trial. Diabetes/Metabolism Research and Reviews, 2022, 38, e3492.	4.0	11
2	Adipose tissue insulin resistance and lipidome alterations as the characterizing factors of nonâ€alcoholic steatohepatitis. European Journal of Clinical Investigation, 2022, 52, e13695.	3.4	24
3	Distinct contributions of metabolic dysfunction and genetic risk factors in the pathogenesis of non-alcoholic fatty liver disease. Journal of Hepatology, 2022, 76, 526-535.	3.7	80
4	TM6SF2/PNPLA3/MBOAT7 Loss-of-Function Genetic Variants Impact on NAFLD Development and Progression Both in Patients and in InÂVitro Models. Cellular and Molecular Gastroenterology and Hepatology, 2022, 13, 759-788.	4.5	44
5	Crosstalk between Irisin Levels, Liver Fibrogenesis and Liver Damage in Non-Obese, Non-Diabetic Individuals with Non-Alcoholic Fatty Liver Disease. Journal of Clinical Medicine, 2022, 11, 635.	2.4	12
6	Why does obesity cause diabetes?. Cell Metabolism, 2022, 34, 11-20.	16.2	183
7	Association of Dietary Patterns with MRI Markers of Hepatic Inflammation and Fibrosis in the MAST4HEALTH Study. International Journal of Environmental Research and Public Health, 2022, 19, 971.	2.6	2
8	Combination therapy with pioglitazone/exenatide/metformin reduces the prevalence of hepatic fibrosis and steatosis: The efficacy and durability of initial combination therapy for type 2 diabetes (<scp>EDICT</scp>). Diabetes, Obesity and Metabolism, 2022, 24, 899-907.	4.4	15
9	Insulin: The master regulator of glucose metabolism. Metabolism: Clinical and Experimental, 2022, 129, 155142.	3.4	78
10	Metabolic dysfunction-associated fatty liver disease: a year in review. Current Opinion in Gastroenterology, 2022, 38, 251-260.	2.3	37
11	Assessment of Exposure to Di-(2-ethylhexyl) Phthalate (DEHP) Metabolites and Bisphenol A (BPA) and Its Importance for the Prevention of Cardiometabolic Diseases. Metabolites, 2022, 12, 167.	2.9	11
12	Obesity-Related Insulin Resistance: The Central Role of Adipose Tissue Dysfunction. Handbook of Experimental Pharmacology, 2022, , 145-164.	1.8	8
13	Prandial hepatic glucose production during hypoglycemia is altered after gastric bypass surgery and sleeve gastrectomy. Metabolism: Clinical and Experimental, 2022, 131, 155199.	3.4	12
14	Editorial: Mechanisms for the Alteration in the Crosstalk Among Insulin-Sensitive Tissues. Frontiers in Endocrinology, 2022, 13, 883659.	3.5	0
15	Effect of tirzepatide versus insulin degludec on liver fat content and abdominal adipose tissue in people with type 2 diabetes (SURPASS-3 MRI): a substudy of the randomised, open-label, parallel-group, phase 3 SURPASS-3 trial. Lancet Diabetes and Endocrinology,the, 2022, 10, 393-406.	11.4	155
16	Prevalence and predictors of non-alcoholic steatohepatitis in subjects with morbid obesity and with or without type 2 diabetes. Diabetes and Metabolism, 2022, 48, 101363.	2.9	11
17	Altered Insulin Clearance after Gastric Bypass and Sleeve Gastrectomy in the Fasting and Prandial Conditions. International Journal of Molecular Sciences, 2022, 23, 7667.	4.1	8
18	Healthy aging: the INTECMAN project. Aging Clinical and Experimental Research, 2021, 33, 2011-2015.	2.9	2

#	Article	IF	Citations
19	Gamma-glutamyltransferase, arterial remodeling and prehypertension in a healthy population at low cardiometabolic risk. Journal of Human Hypertension, 2021, 35, 334-342.	2.2	0
20	SGLT2 inhibitors and thiazide enhance excretion of DEHP toxic metabolites in subjects with type 2 diabetes: A randomized clinical trial. Environmental Research, 2021, 192, 110316.	7.5	9
21	The <scp>Pro12Ala</scp> polymorphism of <scp>PPARÎ³2</scp> modulates beta cell function and failure to oral glucoseâ€lowering drugs in patients with type 2 diabetes. Diabetes/Metabolism Research and Reviews, 2021, 37, e3392.	4.0	2
22	Effect of Mild Physiologic Hyperglycemia on Insulin Secretion, Insulin Clearance, and Insulin Sensitivity in Healthy Glucose-Tolerant Subjects. Diabetes, 2021, 70, 204-213.	0.6	15
23	Adaptation of Insulin Clearance to Metabolic Demand Is a Key Determinant of Glucose Tolerance. Diabetes, 2021, 70, 377-385.	0.6	47
24	Metabolic, reproductive and thyroid effects of bis(2-ethylhexyl) phthalate (DEHP) orally administered to male and female juvenile rats at dose levels derived from children biomonitoring study. Toxicology, 2021, 449, 152653.	4.2	24
25	Krill Oil Supplementation Reduces Exacerbated Hepatic Steatosis Induced by Thermoneutral Housing in Mice with Diet-Induced Obesity. Nutrients, 2021, 13, 437.	4.1	23
26	External Validation of Surrogate Indices of Fatty Liver in the General Population: The Bagnacavallo Study. Journal of Clinical Medicine, 2021, 10, 520.	2.4	15
27	TM6SF2/PNPLA3/MBOAT7 loss-of-function genetic variants impact on NAFLD development and progression both in patients and in in vitro models. Digestive and Liver Disease, 2021, 53, S27-S28.	0.9	1
28	Toxicological Assessment of Oral Co-Exposure to Bisphenol A (BPA) and Bis(2-ethylhexyl) Phthalate (DEHP) in Juvenile Rats at Environmentally Relevant Dose Levels: Evaluation of the Synergic, Additive or Antagonistic Effects. International Journal of Environmental Research and Public Health, 2021, 18, 4584.	2.6	14
29	Liver-targeting drugs and their effect on blood glucose and hepatic lipids. Diabetologia, 2021, 64, 1461-1479.	6.3	21
30	Effect of Mastiha supplementation on NAFLD: The MAST4HEALTH Randomised, Controlled Trial. Molecular Nutrition and Food Research, 2021, 65, e2001178.	3.3	19
31	Changes in Plasma Bioactive Lipids and Inflammatory Markers during a Half-Marathon in Trained Athletes. Applied Sciences (Switzerland), 2021, 11, 4622.	2.5	4
32	Comment on Piccinini and Bergman. The Measurement of Insulin Clearance. Diabetes Care 2020;43:2296â€“2302. Diabetes Care, 2021, 44, e98-e99.	8.6	3
33	Nutrigenetic Interactions Might Modulate the Antioxidant and Anti-Inflammatory Status in Mastiha-Supplemented Patients With NAFLD. Frontiers in Immunology, 2021, 12, 683028.	4.8	12
34	PPARâ€Î³â€induced changes in visceral fat and adiponectin levels are associated with improvement of steatohepatitis in patients with NASH. Liver International, 2021, 41, 2659-2670.	3.9	51
35	New Insights on the Interactions Between Insulin Clearance and the Main Glucose Homeostasis Mechanisms. Diabetes Care, 2021, 44, 2115-2123.	8.6	16
36	Pioglitazone even at low dosage improves NAFLD in type 2 diabetes: clinical and pathophysiological insights from a subgroup of the TOSCA.IT randomised trial. Diabetes Research and Clinical Practice, 2021, 178, 108984.	2.8	43

#	Article	IF	Citations
37	Mastiha has efficacy in immune-mediated inflammatory diseases through a microRNA-155 Th17 dependent action. Pharmacological Research, 2021, 171, 105753.	7.1	17
38	Metabolomics and lipidomics in NAFLD: biomarkers and non-invasive diagnostic tests. Nature Reviews Gastroenterology and Hepatology, 2021, 18, 835-856.	17.8	183
39	Small intestinal metabolism is central to whole-body insulin resistance. Gut, 2021, 70, 1098-1109.	12.1	18
40	Assessment of RANKL/RANK/osteoprotegerin system expression in patients with hepatocellular carcinoma. Minerva Endocrinology, 2021, 46, 367-369.	1.1	1
41	Gluconeogenesis, But Not Glycogenolysis, Contributes to the Increase in Endogenous Glucose Production by SGLT-2 Inhibition. Diabetes Care, 2021, 44, 541-548.	8.6	16
42	Italian Children Exposure to Bisphenol A: Biomonitoring Data from the LIFE PERSUADED Project. International Journal of Environmental Research and Public Health, 2021, 18, 11846.	2.6	7
43	Disparity-filtered differential correlation network analysis: a case study on CRC metabolomics. Journal of Integrative Bioinformatics, 2021, 18, .	1.5	1
44	Metabolite Changes After Metabolic Surgery â€“ Associations to Parameters Reflecting Glucose Homeostasis and Lipid Levels. Frontiers in Endocrinology, 2021, 12, 786952.	3.5	4
45	Insulin resistance, but not insulin response, during oral glucose tolerance test (OGTT) is associated to worse histological outcome in obese NAFLD. Nutrition, Metabolism and Cardiovascular Diseases, 2020, 30, 106-113.	2.6	19
46	Juvenile Toxicity Rodent Model to Study Toxicological Effects of Bisphenol A (BPA) at Dose Levels Derived From Italian Children Biomonitoring Study. Toxicological Sciences, 2020, 173, 387-401.	3.1	9
47	Exenatide and dapagliflozin combination improves markers of liver steatosis and fibrosis in patients with type 2 diabetes. Diabetes, Obesity and Metabolism, 2020, 22, 393-403.	4.4	53
48	Circulating palmitoleic acid is an independent determinant of insulin sensitivity, beta cell function and glucose tolerance in non-diabetic individuals: a longitudinal analysis. Diabetologia, 2020, 63, 206-218.	6.3	37
49	Fatty liver, cardiometabolic disease and mortality. Current Opinion in Lipidology, 2020, 31, 27-31.	2.7	14
50	Noninvasive assessment of hepatic steatosis and fibrosis in patients with severe obesity. Endocrine, 2020, 67, 569-578.	2.3	7
51	Metabolic effects of a prolonged, very-high-dose dietary fructose challenge in healthy subjects. American Journal of Clinical Nutrition, 2020, 111, 369-377.	4.7	22
52	Effects of Probiotic Supplementation on Gastrointestinal, Sensory and Core Symptoms in Autism Spectrum Disorders: A Randomized Controlled Trial. Frontiers in Psychiatry, 2020, 11, 550593.	2.6	86
53	The role of the liver in the modulation of glucose and insulin in non alcoholic fatty liver disease and type 2 diabetes. Current Opinion in Pharmacology, 2020, 55, 165-174.	3.5	24
54	Interplay between Oxidative Stress and Metabolic Derangements in Non-Alcoholic Fatty Liver Disease: The Role of Selenoprotein P. International Journal of Molecular Sciences, 2020, 21, 8838.	4.1	22

#	Article	IF	Citations
55	COVID-19 Infection Pandemic: From the Frontline in Italy. Journal of the American College of Nutrition, 2020, 39, 677-684.	1.8	3
56	Gut-Pancreas-Liver Axis as a Target for Treatment of NAFLD/NASH. International Journal of Molecular Sciences, 2020, 21, 5820.	4.1	38
57	The PNPLA3â€I148M variant increases polyunsaturated triglycerides in human adipose tissue. Liver International, 2020, 40, 2128-2138.	3.9	17
58	Insulin sensitivity depends on the route of glucose administration. Diabetologia, 2020, 63, 1382-1395.	6.3	20
59	Increase in Endogenous Glucose Production With SGLT2 Inhibition Is Unchanged by Renal Denervation and Correlates Strongly With the Increase in Urinary Glucose Excretion. Diabetes Care, 2020, 43, 1065-1069.	8.6	15
60	Relationship between hepatic and systemic angiopoietinâ€like 3, hepatic Vitamin D receptor expression and NAFLD in obesity. Liver International, 2020, 40, 2139-2147.	3.9	25
61	Mechanisms for increased risk of diabetes in chronic liver diseases. Liver International, 2020, 40, 2489-2499.	3.9	9
62	Biomarkers of exposure and early effect in three contaminated sites of southern Italy: protocols for etiological epidemiological studies. BMJ Open, 2020, 10, e036160.	1.9	5
63	Interplay between metabolic derangement, hepatic fibrogenesis and macrophage activation in non-diabetic patients with non-alcoholic fatty liver disease. Digestive and Liver Disease, 2020, 52, e10.	0.9	0
64	Mboat7 down-regulation by hyper-insulinemia induces fat accumulation in hepatocytes. EBioMedicine, 2020, 52, 102658.	6.1	71
65	Impact of using different biomarkers of liver fibrosis on hepatologic referral of individuals with severe obesity and NAFLD. Journal of Endocrinological Investigation, 2020, 43, 1019-1026.	3.3	13
66	Biomonitoring of Bis(2-ethylhexyl)phthalate (DEHP) in Italian children and adolescents: Data from LIFE PERSUADED project. Environmental Research, 2020, 185, 109428.	7.5	26
67	NAFLD and Insulin Resistance: A Multisystemic Disease. , 2020, , 49-71.		1
68	Is there an association between commonly employed biomarkers of liver fibrosis and liver stiffness in the general population?. Annals of Hepatology, 2020, 19, 380-387.	1.5	19
69	Screening for non-alcoholic fatty liver disease in type 2 diabetes using non-invasive scores and association with diabetic complications. BMJ Open Diabetes Research and Care, 2020, 8, e000904.	2.8	71
70	Hydroxysteroid 17-Î² dehydrogenase 13 variant increases phospholipids and protects against fibrosis in nonalcoholic fatty liver disease. JCI Insight, 2020, 5, .	5.0	62
71	Angiopoietin-Like Protein 4 Overexpression in Visceral Adipose Tissue from Obese Subjects with Impaired Glucose Metabolism and Relationship with Lipoprotein Lipase. International Journal of Molecular Sciences, 2020, 21, 7197.	4.1	19
72	1774-P: Neurally Mediated Prandial Islet-Cell Function Is Glucose-Independent and Preserved after Gastric Bypass and Sleeve Gastrectomy. Diabetes, 2020, 69, .	0.6	0

#	Article	IF	Citations
73	352-OR: Combination Therapy with Dapagliflozin plus Exenatide on Endogenous Glucose Production: A Mechanism of Action Study. Diabetes, 2020, 69, 352-OR.	0.6	0
74	153-OR: Glucose-Dependency of Insulinotropic and Glucagonostatic Effects of Glucagon-Like Peptide-1 after Gastric Bypass and Sleeve Gastrectomy. Diabetes, 2020, 69, 153-OR.	0.6	0
75	1836-P: Nonalcoholic Steatohepatitis (NASH) Significantly Contribute to ÃŸ-Cell Function Impairment Independently of Glucose Tolerance Status. Diabetes, 2020, 69, .	0.6	0
76	The imprinted gene Delta like non-canonical notch ligand 1 (Dlk1) associates with obesity and triggers insulin resistance through inhibition of skeletal muscle glucose uptake. EBioMedicine, 2019, 46, 368-380.	6.1	23
77	Crosstalk between adipose tissue insulin resistance and liver macrophages in non-alcoholic fatty liver disease. Journal of Hepatology, 2019, 71, 1012-1021.	3.7	128
78	From NASH to diabetes and from diabetes to NASH: Mechanisms and treatment options. JHEP Reports, 2019, 1, 312-328.	4.9	251
79	PS-006-MBOAT7 downregulation induces hepatic lipid accumulation. Journal of Hepatology, 2019, 70, e8.	3.7	0
80	SAT-323-Selenoprotein P levels discriminate the degree of hepatic steatosis and are related to the NAS score in patients with non-alcoholic fatty liver disease. Journal of Hepatology, 2019, 70, e782.	3.7	0
81	FRI-283-Impact on NAFLD of long-term weight loss after bariatric surgery. Journal of Hepatology, 2019, 70, e520.	3.7	0
82	Mechanism of Action of Inhaled Insulin on Whole Body Glucose Metabolism in Subjects with Type 2 Diabetes Mellitus. International Journal of Molecular Sciences, 2019, 20, 4230.	4.1	3
83	Brain leptin reduces liver lipids by increasing hepatic triglyceride secretion and lowering lipogenesis. Nature Communications, 2019, 10, 2717.	12.8	70
84	Bile acid changes after metabolic surgery are linked to improvement in insulin sensitivity. British Journal of Surgery, 2019, 106, 1178-1186.	0.3	29
85	Metabolomic profile of morbidly obese NAFLD: effect of weight loss by exenatide or diet. Digestive and Liver Disease, 2019, 51, e30.	0.9	0
86	SAT-290-Association of liver inflammation and fibrosis score with noninvasive biomarkers in non-alcoholic fatty liver disease: Preliminary results from the MAST4HEALTH study. Journal of Hepatology, 2019, 70, e765.	3.7	0
87	Selenoprotein P levels discriminate the degree of hepatic steatosis and are related to the NAS score in patients with non-alcoholic fatty liver disease. Digestive and Liver Disease, 2019, 51, e26.	0.9	0
88	Phthalates Exposure as Determinant of Albuminuria in Subjects With Type 2 Diabetes: A Cross-Sectional Study. Journal of Clinical Endocrinology and Metabolism, 2019, 104, 1491-1499.	3.6	16
89	Beta-cell sensitivity to insulinotropic gut hormones is reduced after gastric bypass surgery. Gut, 2019, 68, 1838-1845.	12.1	16
90	Role of vagal activation in postprandial glucose metabolism after gastric bypass in individuals with and without hypoglycaemia. Diabetes, Obesity and Metabolism, 2019, 21, 1513-1517.	4.4	8

#	Article	IF	Citations
91	Women-specific predictors of cardiovascular disease risk - new paradigms. International Journal of Cardiology, 2019, 286, 190-197.	1.7	49
92	27th Annual Meeting of the European Group for the study of Insulin Resistance, Lisbon, Portugal, 8â€“9th May 2019. Cardiovascular Endocrinology and Metabolism, 2019, 8, 88-89.	1.1	0
93	Predictive models with the use of omics and supervised machine learning to diagnose non-alcoholic fatty liver disease: A â€œnon-invasive alternativeâ€•to liver biopsy?. Metabolism: Clinical and Experimental, 2019, 101, 154010.	3.4	14
94	Altered Metabolic Profile and Adipocyte Insulin Resistance Mark Severe Liver Fibrosis in Patients with Chronic Liver Disease. International Journal of Molecular Sciences, 2019, 20, 6333.	4.1	24
95	Inflammatory Biomarkers are Correlated with Some Forms of Regressive Autism Spectrum Disorder. Brain Sciences, 2019, 9, 366.	2.3	25
96	Exenatide regulates pancreatic islet integrity and insulin sensitivity in the nonhuman primate baboon Papio hamadryas. JCI Insight, 2019, 4, .	5.0	15
97	Association of serum lipids with Î²-cell function in obese children and adolescents. Endocrine Connections, 2019, 8, 1318-1323.	1.9	2
98	Reduced insulin clearance relates to increased liver fat content in recent-onset type 2 diabetes and to impaired glucose control in recent-onset type 1 diabetes. , 2019, 14, .		0
99	245-OR: Glucose Production and Utilization following Oral Glucose Load in Type 2 Diabetes Patients Treated with Dapagliflozin Alone and in Saxagliptin Combination. Diabetes, 2019, 68, 245-OR.	0.6	1
100	1888-P: Impaired Insulin Clearance Relates to Increased Liver Fat Content in Recent-Onset Type 2 Diabetes and to Impaired Glucose Control in Recent-Onset Type 1 Diabetes. Diabetes, 2019, 68, .	0.6	0
101	1840-P: Pioglitazone Increases Metabolic Insulin Clearance (MCRI) in IGT Subjects: The ACT NOW Study. Diabetes, 2019, 68, .	0.6	0
102	155-LB: The Increase in Endogenous Glucose Production with SGLT2 Inhibition Is Unchanged by Renal Denervation but Highly Correlates to Urinary Glucose Excretion. Diabetes, 2019, 68, .	0.6	0
103	Cardiometabolic risk and subclinical vascular damage assessment in idiopathic inflammatory myopathies: a challenge for the clinician. Clinical and Experimental Rheumatology, 2019, 37, 1036-1043.	0.8	0
104	Betaâ€•cell sensitivity to glucose is impaired after gastric bypass surgery. Diabetes, Obesity and Metabolism, 2018, 20, 872-878.	4.4	19
105	P.09.3 LACK OF NLRP3-INFLAMMASOME LEADS TO GUT-LIVER AXIS DERANGEMENT, GUT DYSBIOSIS AND A WORSENED PHENOTYPE IN A MOUSE MODEL OF NAFLD. Digestive and Liver Disease, 2018, 50, e217.	0.9	0
106	Bile acid composition modulates insulin resistance in non-diabetic patients with NAFLD. Digestive and Liver Disease, 2018, 50, 17.	0.9	2
107	The antidepressant fluoxetine acts on energy balance and leptin sensitivity via BDNF. Scientific Reports, 2018, 8, 1781.	3.3	32
108	Saturated fat is more metabolically harmful for the human liver than polyunsaturated fat or simple sugars. Journal of Hepatology, 2018, 68, S836.	3.7	3

#	Article	IF	Citations
109	Vitamin D Supplementation in Patients With Type 2 Diabetes: The Vitamin D for Established Type 2 Diabetes (DDM2) Study. Journal of the Endocrine Society, 2018, 2, 310-321.	0.2	33
110	Reply. Hepatology, 2018, 67, 1178-1180.	7.3	0
111	Altered amino acid concentrations in NAFLD: Impact of obesity and insulin resistance. Hepatology, 2018, 67, 145-158.	7.3	296
112	Prevalence of and risk factors for fatty liver in the general population of Northern Italy: the Bagnacavallo Study. BMC Gastroenterology, 2018, 18, 177.	2.0	23
113	Effects of intravenous AICAR (5-aminoimidazole-4-carboximide riboside) administration on insulin signaling and resistance in premature baboons, Papio sp.. PLoS ONE, 2018, 13, e0208757.	2.5	2
114	In non obese NAFLD increased plasma saturated fatty acids and insulin resistance are metabolic signatures of severity of liver disease. Journal of Hepatology, 2018, 68, S566.	3.7	0
115	Saturated Fat Is More Metabolically Harmful for the Human Liver Than Unsaturated Fat or Simple Sugars. Diabetes Care, 2018, 41, 1732-1739.	8.6	266
116	Predisposition to diabetes is related to insulin resistance in NAFLD patients and to decreased insulin secretion in HCV patients. Journal of Hepatology, 2018, 68, S835.	3.7	1
117	Interaction of GLP-1 and Ghrelin on Glucose Tolerance in Healthy Humans. Diabetes, 2018, 67, 1976-1985.	0.6	25
118	The LIFE PERSUADED project approach on phthalates and bisphenol A biomonitoring in Italian mother-child pairs linking exposure and juvenile diseases. Environmental Science and Pollution Research, 2018, 25, 25618-25625.	5.3	16
119	Older Subjects With Î²-Cell Dysfunction Have an Accentuated Incretin Release. Journal of Clinical Endocrinology and Metabolism, 2018, 103, 2613-2619.	3.6	16
120	Bile acid composition modulate insulin resistance in non-diabetic patients with NAFLD. Journal of Hepatology, 2018, 68, S338.	3.7	1
121	Impact of short term weight loss (very low calorie diet vs bariatric surgery) on hepatic insulin resistance and plasma lipidomic profile. Journal of Hepatology, 2018, 68, S817.	3.7	0
122	Beneficial Effects of RYGB on ÃŸ-Cell Function and Hepatic and Peripheral Insulin Sensitivity Are Maintained Seven Years after Surgery in Both Diabetic and Nondiabetic Subjects. Diabetes, 2018, 67, 2089-P.	0.6	2
123	Digital liver biopsy: Bio-imaging of fatty liver for translational and clinical research. World Journal of Hepatology, 2018, 10, 231-245.	2.0	18
124	Lean Subjects with Fatty Liver Show Decreased GLP-1 and GIP Response during OGTT. Diabetes, 2018, 67, 1869-P.	0.6	0
125	Role of Adipose Tissue Insulin Resistance in the Natural History of Type 2 Diabetes: Results From the San Antonio Metabolism Study. Diabetes, 2017, 66, 815-822.	0.6	234
126	Response to: Drug therapy for ectopic fat: myth or reality?. Expert Review of Cardiovascular Therapy, 2017, 15, 73-74.	1.5	0

#	Article	IF	Citations
127	AISF position paper on nonalcoholic fatty liver disease (NAFLD): Updates and future directions. Digestive and Liver Disease, 2017, 49, 471-483.	0.9	254
128	An extended fatty liver index to predict non-alcoholic fatty liver disease. Diabetes and Metabolism, 2017, 43, 229-239.	2.9	22
129	Hepatic Insulin Resistance and Altered Gluconeogenic Pathway in Premature Baboons. Endocrinology, 2017, 158, 1140-1151.	2.8	9
130	Gamma-glutamyltransferase, fatty liver index and hepatic insulin resistance are associated with incident hypertension in two longitudinal studies. Journal of Hypertension, 2017, 35, 493-500.	0.5	57
131	Glucose kinetics. Current Opinion in Clinical Nutrition and Metabolic Care, 2017, 20, 300-309.	2.5	17
132	Novel hepatoâ€preferential basal insulin peglispro (<scp>BIL</scp>) does not differentially affect insulin sensitivity compared with insulin glargine in patients with type 1 and type 2 diabetes. Diabetes, Obesity and Metabolism, 2017, 19, 482-488.	4.4	0
133	Effect of exenatide on postprandial glucose fluxes, lipolysis, and ÃŸâ€cell function in nonâ€diabetic, morbidly obese patients. Diabetes, Obesity and Metabolism, 2017, 19, 412-420.	4.4	15
134	The combination of mucus-degrading gram-negative bacteria and reduced antimicrobial peptides drives adipose tissue inflammation and NAFLD progression in mice lacking NLRP3-inflammasome. Digestive and Liver Disease, 2017, 49, e2-e3.	0.9	0
135	Response to Comment on Gastaldelli et al. Short-term Effects of Laparoscopic Adjustable Gastric Banding Versus Roux-en-Y Gastric Bypass. Diabetes Care 2016;39:1925â€“1931. Diabetes Care, 2017, 40, e50-e50.	8.6	0
136	Increased hepatic glucose production and insulin resistance are associated to increased plasma concentrations of glucogenic amino acids in subjects with NAFLD. Digestive and Liver Disease, 2017, 49, e1.	0.9	1
137	Increased FNDC5/Irisin expression in human hepatocellular carcinoma. Peptides, 2017, 88, 62-66.	2.4	52
138	The color of fat and its central role in the development and progression of metabolic diseases. Hormone Molecular Biology and Clinical Investigation, 2017, 31, .	0.7	7
139	Pioglitazone Improves Left Ventricular Diastolic Function in Subjects With Diabetes. Diabetes Care, 2017, 40, 1530-1536.	8.6	45
140	Lack of NLRP3-inflammasome leads to gut-liver axis derangement, gut dysbiosis and a worsened phenotype in a mouse model of NAFLD. Scientific Reports, 2017, 7, 12200.	3.3	57
141	Muscle and adipose tissue morphology, insulin sensitivity and beta-cell function in diabetic and nondiabetic obese patients: effects of bariatric surgery. Scientific Reports, 2017, 7, 9007.	3.3	62
142	Increased hepatic glucose production and insulin resistance in subjects with non-alcoholic fatty liver disease is associated to increased plasma concentrations of glucogenic amino acids. Journal of Hepatology, 2017, 66, S163.	3.7	0
143	Osteopontin in hepatocellular carcinoma: A possible biomarker for diagnosis and follow-up. Cytokine, 2017, 99, 59-65.	3.2	45
144	Insulin resistance and reduced metabolic flexibility: cause or consequence of NAFLD?. Clinical Science, 2017, 131, 2701-2704.	4.3	80

#	Article	IF	Citations
145	Use of HOMA-IR to diagnose non-alcoholic fatty liver disease: a population-based and inter-laboratory study. Diabetologia, 2017, 60, 1873-1882.	6.3	85
146	Chronic Intranasal Insulin Does Not Affect Hepatic Lipids but Lowers Circulating BCAAs in Healthy Male Subjects. Journal of Clinical Endocrinology and Metabolism, 2017, 102, 1325-1332.	3.6	11
147	The combination of mucus-degrading gram-negative bacteria and reduced antimicrobial peptides drives adipose tissue inflammation and non-alcoholic fatty liver disease progression in mice lacking NLRP3-inflammasome. Journal of Hepatology, 2017, 66, S16.	3.7	2
148	Glucagon-like Peptide-1 and the Central/Peripheral Nervous System: Crosstalk in Diabetes. Trends in Endocrinology and Metabolism, 2017, 28, 88-103.	7.1	88
149	Pathophysiology of Non Alcoholic Fatty Liver Disease. International Journal of Molecular Sciences, 2016, 17, 2082.	4.1	126
150	Aleglitazar, a dual peroxisome proliferatorâ€activated receptorâ€Î±/Î³ agonist, improves insulin sensitivity, glucose control and lipid levels in people with type 2 diabetes: findings from a randomized, doubleâ€blind trial. Diabetes, Obesity and Metabolism, 2016, 18, 711-715.	4.4	12
151	Ectopic fat: a target for cardiometabolic risk management. Expert Review of Cardiovascular Therapy, 2016, 14, 1301-1303.	1.5	8
152	Peripheral insulin resistance predicts liver damage in nondiabetic subjects with nonalcoholic fatty liver disease. Hepatology, 2016, 63, 107-116.	7.3	67
153	Lack of NLRP3-inflammasome leads to gut-liver axis derangement and increases hepatic injury in a mouse model of NAFLD. Digestive and Liver Disease, 2016, 48, e9-e10.	0.9	0
154	Adipose tissue insulin resistance is associated with macrophage activation in non-diabetic patients with non-alcoholic fatty liver disease. Digestive and Liver Disease, 2016, 48, e12.	0.9	1
155	Angiopoietin-like4 is associated with lipid metabolism and severe fibrosis in non-diabetic patients with non-alcoholic fatty liver disease. Digestive and Liver Disease, 2016, 48, e38.	0.9	0
156	EASLâ€“EASDâ€“EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. Diabetologia, 2016, 59, 1121-1140.	6.3	485
157	EASLâ€“EASDâ€“EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. Journal of Hepatology, 2016, 64, 1388-1402.	3.7	3,403
158	EASL-EASD-EASO Clinical Practice Guidelines for the Management of Non-Alcoholic Fatty Liver Disease. Obesity Facts, 2016, 9, 65-90.	3.4	371
159	Ghrelin Impairs Prandial Glucose Tolerance and Insulin Secretion in Healthy Humans Despite Increasing GLP-1. Journal of Clinical Endocrinology and Metabolism, 2016, 101, 2405-2414.	3.6	35
160	Short-term Effects of Laparoscopic Adjustable Gastric Banding Versus Roux-en-Y Gastric Bypass. Diabetes Care, 2016, 39, 1925-1931.	8.6	35
161	Exenatide Exerts Its Positive Effects on Liver by Reducing both Hepatic and Adipose Tissue Insulin Resistance. Journal of Hepatology, 2016, 64, S171.	3.7	0
162	Evaluation of Metabolic Parameters of Hepatic Dysfunction in Subjects with Hepatocellular Carcinoma and their Change after Liver Transplantation: A Metabolomic Approach. Journal of Hepatology, 2016, 64, S316.	3.7	0

#	Article	IF	Citations
163	Angiopoietin-Like4 is Associated with Lipid Metabolism and Severe Fibrosis in Non-Diabetic Patients with Non-Alcoholic Fatty Liver Disease. Journal of Hepatology, 2016, 64, S477.	3.7	0
164	Lack of NLRP3-Inflammasome Leads to Gut-Liver AXIS Derangement and Increases Hepatic Injury in a Mouse Model of Non-Alcoholic Fatty Liver Disease. Journal of Hepatology, 2016, 64, S679.	3.7	1
165	Glucose uptake saturation explains glucose kinetics profiles measured by different tests. American Journal of Physiology - Endocrinology and Metabolism, 2016, 311, E346-E357.	3.5	7
166	Exenatide improves both hepatic and adipose tissue insulin resistance: A dynamic positron emission tomography study. Hepatology, 2016, 64, 2028-2037.	7.3	78
167	Adipose Tissue Insulin Resistance is Associated with Macrophage Activation in Non-Diabetic Patients with Non-Alcoholic Fatty Liver Disease. Journal of Hepatology, 2016, 64, S476.	3.7	0
168	Genome-scale study reveals reduced metabolic adaptability in patients with non-alcoholic fatty liver disease. Nature Communications, 2016, 7, 8994.	12.8	103
169	Time for Glucagon like peptide-1 receptor agonists treatment for patients with NAFLD?. Journal of Hepatology, 2016, 64, 262-264.	3.7	30
170	Early effect of Roux-en-Y gastric bypass on insulin sensitivity and signaling. Surgery for Obesity and Related Diseases, 2016, 12, 42-47.	1.2	9
171	Gutâ€“liver axis derangement due to lack of inflammasome activity leads to visceral obesity and NASH development. Digestive and Liver Disease, 2015, 47, e4.	0.9	0
172	The Subtle Balance between Lipolysis and Lipogenesis: A Critical Point in Metabolic Homeostasis. Nutrients, 2015, 7, 9453-9474.	4.1	354
173	Not all fats are created equal: adipose vs. ectopic fat, implication in cardiometabolic diseases. Hormone Molecular Biology and Clinical Investigation, 2015, 22, 7-18.	0.7	39
174	Effects of sitagliptin on ectopic fat contents and glucose metabolism in type 2 diabetic patients with fatty liver: A pilot study. Journal of Diabetes Investigation, 2015, 6, 164-172.	2.4	23
175	Peripheral Insulin Resistance and Impaired Insulin Signaling Contribute to Abnormal Glucose Metabolism in Preterm Baboons. Endocrinology, 2015, 156, 813-823.	2.8	29
176	Exenatide Regulates Cerebral Glucose Metabolism in Brain Areas Associated With Glucose Homeostasis and Reward System. Diabetes, 2015, 64, 3406-3412.	0.6	45
177	Liver damage can be associated with deregulation of the de novo lipogenesis pathway in subjects with Non Alcoholic Fatty Liver Disease. Digestive and Liver Disease, 2015, 47, e5.	0.9	0
178	O064 : Gut-liver axis derangement due to lack of inflammasome activity leads to visceral obesity and nash development. Journal of Hepatology, 2015, 62, S223.	3.7	0
179	P0519 : Lipidomics reveals that low plasma unsaturated to saturated fat ratios are biomarkers of NAFLD and liver damage. Journal of Hepatology, 2015, 62, S509.	3.7	0
180	P1056 : Insulin resistance and liver damage are associated with early signs of left ventricular systolic dysfunction in patients with nonalcoholic fatty liver disease, independently of diabetes, hypertension and dyslipidemia. Journal of Hepatology, 2015, 62, S744-S745.	3.7	0

#	Article	IF	Citations
181	P1042 : Deregulation of de novo lipogenesis can be associated with liver damage in patients with non alcoholic fatty liver disease. Journal of Hepatology, 2015, 62, S738.	3.7	0
182	Glucose Metabolism in High-Risk Subjects for Type 2 Diabetes Carrying the rs7903146TCF7L2Gene Variant. Journal of Clinical Endocrinology and Metabolism, 2015, 100, E1160-E1167.	3.6	15
183	Nonalcoholic Fatty Liver Disease and Type 2 Diabetes: Common Pathophysiologic Mechanisms. Current Diabetes Reports, 2015, 15, 607.	4.2	102
184	The effect of muraglitazar on adiponectin signalling, mitochondrial function and fat oxidation genes in human skeletal muscle in vivo. Diabetic Medicine, 2015, 32, 657-664.	2.3	7
185	Brown versus white fat: are they really playing a role in obesity and cardiometabolic risk?. Clinical Lipidology, 2015, 10, 365-368.	0.4	1
186	Neurophysiological and Behavioural Variables in Cognitive Impairment: Towards a Personalised Monitoring System. Biosystems and Biorobotics, 2015, , 407-417.	0.3	1
187	Obesity and carotid artery remodeling. Nutrition and Diabetes, 2015, 5, e177-e177.	3.2	14
188	Comparison of Liver Fat Indices for the Diagnosis of Hepatic Steatosis and Insulin Resistance. PLoS ONE, 2014, 9, e94059.	2.5	124
189	HCC Development Is Associated to Peripheral Insulin Resistance in a Mouse Model of NASH. PLoS ONE, 2014, 9, e97136.	2.5	76
190	The Disposition Index Does Not Reflect Î²-Cell Function in IGT Subjects Treated With Pioglitazone. Journal of Clinical Endocrinology and Metabolism, 2014, 99, 3774-3781.	3.6	34
191	The good and bad effects of statins on insulin sensitivity and secretion. Endocrine Research, 2014, 39, 137-143.	1.2	27
192	Baseline Adiponectin Levels Do Not Influence the Response to Pioglitazone in ACT NOW. Diabetes Care, 2014, 37, 1706-1711.	8.6	11
193	Motor Activity in Aging: An Integrated Approach for Better Quality of Life. International Scholarly Research Notices, 2014, 2014, 1-9.	0.9	3
194	Corrigendum to â€œInsulin resistance, adipose depots and gut: Interactions and pathological implicationsâ€•[Dig. Liver Dis. 42 (2010) 310â€“319]. Digestive and Liver Disease, 2014, 46, 1055.	0.9	0
195	P843 ALTERATION IN GLUCOSE METABOLISM AFTER AN ORAL GLUCOSE LOAD AND RELATIONSHIP WITH LIVER DAMAGE IN PATIENTS WITH NAFLD. Journal of Hepatology, 2014, 60, S352-S353.	3.7	0
196	P857 A NEW INDEX OF GLUTATHIONE TURNOVER (GSH_TI) AND ITS ASSOCIATION WITH SEVERITY OF NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD). Journal of Hepatology, 2014, 60, S357-S358.	3.7	0
197	A direct comparison of longâ€•and shortâ€acting <scp>GLP</scp>â€1 receptor agonists (taspoglutide once) Tj ETQq1 1 0.784314 rg Obesity and Metabolism, 2014, 16, 170-178.	4.4	8
198	Alteration in glucose metabolism after an oral glucose load in patients with non-alcoholic fatty liver disease. Digestive and Liver Disease, 2014, 46, e54.	0.9	0

#	Article	IF	Citations
199	Altered pattern of the incretin effect as assessed by modelling in individuals with glucose tolerance ranging from normal to diabetic. Diabetologia, 2014, 57, 1199-1203.	6.3	46
200	Evidence from a single individual that increased plasma GLP-1 and GLP-1-stimulated insulin secretion after gastric bypass are independent of foregut exclusion. Diabetologia, 2014, 57, 1495-1499.	6.3	16
201	Relationship between glucose metabolism and non-alcoholic fatty liver disease severity in morbidly obese women. Journal of Endocrinological Investigation, 2014, 37, 739-744.	3.3	11
202	Matched weight loss induced by sleeve gastrectomy or gastric bypass similarly improves metabolic function in obese subjects. Obesity, 2014, 22, 2026-2031.	3.0	50
203	P849 QUANTITATIVE AND QUALITATIVE ANALYSIS OF PLASMA FREE FATTY ACIDS AND THEIR IMPACT ON LIVER DAMAGE IN NAFLD PATIENTS. Journal of Hepatology, 2014, 60, S354-S355.	3.7	0
204	Alteration in lipid metabolism after an oral fat load in non-alcoholic fatty liver disease. Digestive and Liver Disease, 2014, 46, e53-e54.	0.9	0
205	Blockade of Glucagon-like Peptide 1 Receptor Corrects Postprandial Hypoglycemia After Gastric Bypass. Gastroenterology, 2014, 146, 669-680.e2.	1.3	229
206	Effects of glucose and fat load on oxidative stress in patients with non-alcoholic fatty liver disease. Digestive and Liver Disease, 2014, 46, e54.	0.9	0
207	P845 IMPACT OF FAT VERSUS GLUCOSE LOAD ON OXIDATIVE STRESS IN NON-ALCOHOLIC FATTY LIVER DISEASE. Journal of Hepatology, 2014, 60, S353.	3.7	0
208	Altered Islet Function and Insulin Clearance Cause Hyperinsulinemia in Gastric Bypass Patients With Symptoms of Postprandial Hypoglycemia. Journal of Clinical Endocrinology and Metabolism, 2014, 99, 2008-2017.	3.6	107
209	P840 ALTERATION IN LIPID METABOLISM AFTER AN ORAL FAT LOAD IN PATIENTS WITH NAFLD. Journal of Hepatology, 2014, 60, S352.	3.7	1
210	The effect of chronic twice daily exenatide treatment on Î²â€cell function in new onset type 2 diabetes. Clinical Endocrinology, 2014, 80, 545-553.	2.4	22
211	White and Brown Adipose Tissue Development. , 2014, , 237-246.		1
212	Albiglutide for the treatment of type 2 diabetes mellitus. Drugs of Today, 2014, 50, 665.	1.1	7
213	Pathophysiology of Prediabetes: Role of Lipotoxicity?. , 2014, , 31-47.		2
214	Circulating Lysophosphatidylcholines Are Markers of a Metabolically Benign Nonalcoholic Fatty Liver. Diabetes Care, 2013, 36, 2331-2338.	8.6	100
215	Pioglitazone improves glucose metabolism and modulates skeletal muscle TIMP-3â€“TACE dyad in type 2 diabetes mellitus: a randomised, double-blind, placebo-controlled, mechanistic study. Diabetologia, 2013, 56, 2153-2163.	6.3	71
216	Validation of [18F]fluorodeoxyglucose and positron emission tomography (PET) for the measurement of intestinal metabolism in pigs, and evidence of intestinal insulin resistance in patients with morbid obesity. Diabetologia, 2013, 56, 893-900.	6.3	37

#	Article	IF	Citations
217	Direct effect of GLP-1 infusion on endogenous glucose production in humans. Diabetologia, 2013, 56, 156-161.	6.3	117
218	Prevention of Diabetes With Pioglitazone in ACT NOW. Diabetes, 2013, 62, 3920-3926.	0.6	83
219	Prediction of Diabetes Based on Baseline Metabolic Characteristics in Individuals at High Risk. Diabetes Care, 2013, 36, 3607-3612.	8.6	55
220	Preserved GLP-1 and exaggerated GIP secretion in type 2 diabetes and relationships with triglycerides and ALT. European Journal of Endocrinology, 2013, 169, 421-430.	3.7	52
221	1351 CONTRIBUTION OF VISCERAL FAT AND HEPATIC FAT TO METABOLIC DERANGEMENTS AND LIVER DAMAGE IN NAFLD PATIENTS. Journal of Hepatology, 2013, 58, S543-S544.	3.7	0
222	Increased carotid intima-media thickness in the physiologic range is associated with impaired postprandial glucose metabolism, insulin resistance and beta cell dysfunction. Atherosclerosis, 2013, 229, 277-281.	0.8	16
223	73 KR ÃœPPEL LIKE FACTOR 6 (KLF6) PROTECTS FROM NAFLD PROGRESSION THROUGH REGULATION OF ADIPOSE TISSUE INSULIN RESISTANCE. Journal of Hepatology, 2013, 58, S33.	3.7	0
224	Eight weeks of treatment with long-acting GLP-1 analog taspoglutide improves postprandial insulin secretion and sensitivity in metformin-treated patients with type 2 diabetes. Metabolism: Clinical and Experimental, 2013, 62, 1330-1339.	3.4	12
225	1365 METABOLIC ALTERATIONS OF LIPID KINETICS IN NAFLD PATIENTS AND THEIR CONTRIBUTION TO LIVER DAMAGE. Journal of Hepatology, 2013, 58, S549.	3.7	0
226	Metabolic response to high-carbohydrate and low-carbohydrate meals in a nonhuman primate model. American Journal of Physiology - Endocrinology and Metabolism, 2013, 304, E444-E451.	3.5	19
227	Non-Alcoholic Fatty Liver Disease (NAFLD) and Its Connection with Insulin Resistance, Dyslipidemia, Atherosclerosis and Coronary Heart Disease. Nutrients, 2013, 5, 1544-1560.	4.1	648
228	Metabolic Consequences of Adipose Triglyceride Lipase Deficiency in Humans: An In Vivo Study in Patients With Neutral Lipid Storage Disease With Myopathy. Journal of Clinical Endocrinology and Metabolism, 2013, 98, E1540-E1548.	3.6	23
229	Biliopancreatic Diversion in Nonobese Patients With Type 2 Diabetes: Impact and Mechanisms. Journal of Clinical Endocrinology and Metabolism, 2013, 98, 2765-2773.	3.6	57
230	Imaging cardiac fat. European Heart Journal Cardiovascular Imaging, 2013, 14, 625-630.	1.2	36
231	Long-Term Effects of Bariatric Surgery on Meal Disposal and Î²-Cell Function in Diabetic and Nondiabetic Patients. Diabetes, 2013, 62, 3709-3717.	0.6	98
232	Ectopic fat: the true culprit linking obesity and cardiovascular disease?. Thrombosis and Haemostasis, 2013, 110, 651-660.	3.4	51
233	Insulin Resistance and Endothelial Dysfunction: A Mutual Relationship in Cardiometabolic Risk. Current Pharmaceutical Design, 2013, 19, 2420-2431.	1.9	37
234	A Pilot Randomised Study of the Metabolic and Histological Effects of Exercise in Non-alcoholic Steatohepatitis. Journal of Diabetes & Metabolism, 2013, 04, .	0.2	6

#	Article	IF	Citations
235	Importance of liver fat indices for diagnosis of hepatic steatosis. Experimental and Clinical Endocrinology and Diabetes, 2013, 121, .	1.2	0
236	The ontogeny of the endocrine pancreas in the fetal/newborn baboon. Journal of Endocrinology, 2012, 214, 289-299.	2.6	20
237	The role of cardiac fat in insulin resistance. Current Opinion in Clinical Nutrition and Metabolic Care, 2012, 15, 523-528.	2.5	22
238	Diabetes and Nonalcoholic Fatty Liver Disease. Experimental Diabetes Research, 2012, 2012, 1-2.	3.8	3
239	Diet and Exercise in the Treatment of Fatty Liver. Journal of Nutrition and Metabolism, 2012, 2012, 1-2.	1.8	5
240	Integrated Physiology/Obesity. Diabetes, 2012, 61, A443-A522.	0.6	2
241	Dynamics of Circulating Ligands and Soluble Receptor for Advanced Glycation End-Product in Liver Transplantation. Transplantation, 2012, 94, 305.	1.0	0
242	Dynamics of Circulating Ligands and Soluble Receptor for Advanced Glycation End-Product in Liver Transplantation. Transplantation, 2012, 94, 653.	1.0	0
243	215 THE RECEPTOR FOR ADVANCED GLYCATION ENDPRODUCTS (RAGE) AXIS IN LIVER TRANSPLANTATION. Journal of Hepatology, 2012, 56, S91.	3.7	0
244	Estimation of prehepatic insulin secretion: comparison between standardized C-peptide and insulin kinetic models. Metabolism: Clinical and Experimental, 2012, 61, 434-443.	3.4	18
245	1310 PERIPHERAL INSULIN RESISTANCE RATHER THAN HEPATIC IS A PRIMARY DEFECT IN NON OBESE, NON DIABETIC, NON DYSLIPIDEMIC NAFLD PATIENTS: CORRELATION WITH LIVER DAMAGE. Journal of Hepatology, 2012, 56, S516.	3.7	0
246	1290 THE EFFECT OF EXERCISE ON THE METABOLIC AND HISTOLOGICAL FEATURES OF NON-ALCOHOLIC FATTY LIVER DISEASE. Journal of Hepatology, 2012, 56, S509.	3.7	3
247	Hepatic and Cardiac Steatosis. Heart Failure Clinics, 2012, 8, 663-670.	2.1	19
248	Mechanisms for the Antihyperglycemic Effect of Sitagliptin in Patients with Type 2 Diabetes. Journal of Clinical Endocrinology and Metabolism, 2012, 97, 2818-2826.	3.6	91
249	Relationship between fatty liver and glucose metabolism: A cross-sectional study in 571 obese children. Nutrition, Metabolism and Cardiovascular Diseases, 2012, 22, 120-126.	2.6	47
250	Effects of Adding Exercise to a 16-Week Very Low-Calorie Diet in Obese, Insulin-Dependent Type 2 Diabetes Mellitus Patients. Journal of Clinical Endocrinology and Metabolism, 2012, 97, 2512-2520.	3.6	57
251	Glucokinase links KrÃ¼ppel-like factor 6 to the regulation of hepatic insulin sensitivity in nonalcoholic fatty liver disease. Hepatology, 2012, 55, 1083-1093.	7.3	55
252	Effect of adipose tissue insulin resistance on metabolic parameters and liver histology in obese patients with nonalcoholic fatty liver disease. Hepatology, 2012, 55, 1389-1397.	7.3	348

#	Article	IF	Citations
253	Fatty liver index, gamma-glutamyltransferase, and early carotid plaques. Hepatology, 2012, 55, 1406-1415.	7.3	118
254	Plasma sCD36 is associated with markers of atherosclerosis, insulin resistance and fatty liver in a nondiabetic healthy population. Journal of Internal Medicine, 2012, 271, 294-304.	6.0	68
255	Impact of increased visceral and cardiac fat on cardiometabolic risk and disease. Diabetic Medicine, 2012, 29, 622-627.	2.3	85
256	Gastric bypass and banding equally improve insulin sensitivity and Î² cell function. Journal of Clinical Investigation, 2012, 122, 4667-4674.	8.2	222
257	Fatty Liver Index Predicts Further Metabolic Deteriorations in Women with Previous Gestational Diabetes. PLoS ONE, 2012, 7, e32710.	2.5	49
258	Impact of percent body fat on oral glucose tolerance testing: a cross-sectional study in 1512 obese children. Journal of Endocrinological Investigation, 2012, 35, 893-6.	3.3	3
259	1264 CRITICAL ROLE OF TRIGLYCERIDES AND LONG CHAIN FATTY ACYL COA ACCUMULATION IN LIVER INSULIN RESISTANCE IN THE BABOON. A NEW NON-HUMAN PRIMATE MODEL OF NAFLD. Journal of Hepatology, 2011, 54, S499.	3.7	0
260	Pericardial Rather Than Epicardial Fat is a Cardiometabolic Risk Marker: An MRI vs Echo Study. Journal of the American Society of Echocardiography, 2011, 24, 1156-1162.	2.8	105
261	Pathophysiology ofÂPrediabetes. Medical Clinics of North America, 2011, 95, 327-339.	2.5	124
262	Protective role of adiponectin on endothelial dysfunction induced by AGEs: A clinical and experimental approach. Microvascular Research, 2011, 82, 73-76.	2.5	28
263	Role of beta-cell dysfunction, ectopic fat accumulation and insulin resistance in the pathogenesis of type 2 diabetes mellitus. Diabetes Research and Clinical Practice, 2011, 93, S60-S65.	2.8	94
264	842 PREDISPOSITION TO DEVELOP DIABETES IN SUBJECTS WITH NAFLD IS RELATED TO INSULIN RESISTANCE RATHER THAN TO DECREASED B-CELL FUNCTION. Journal of Hepatology, 2011, 54, S336-S337.	3.7	0
265	Ectopic Fat Storage, Insulin Resistance, and Hypertension. Current Pharmaceutical Design, 2011, 17, 3074-3080.	1.9	22
266	Metabolic effects of muraglitazar in type 2 diabetic subjects. Diabetes, Obesity and Metabolism, 2011, 13, 893-902.	4.4	13
267	Glucagonâ€like peptideâ€1 receptor activation stimulates hepatic lipid oxidation and restores hepatic signalling alteration induced by a highâ€fat diet in nonalcoholic steatohepatitis. Liver International, 2011, 31, 1285-1297.	3.9	337
268	Early and longer term effects of gastric bypass surgery on tissue-specific insulin sensitivity and beta cell function in morbidly obese patients with and without type 2 diabetes. Diabetologia, 2011, 54, 2093-2102.	6.3	183
269	What is the role of the receptor for advanced glycation end products-ligand axis in liver injury?. Liver Transplantation, 2011, 17, 633-640.	2.4	46
270	Effect of Exenatide on Splanchnic and Peripheral Glucose Metabolism in Type 2 Diabetic Subjects. Journal of Clinical Endocrinology and Metabolism, 2011, 96, 1763-1770.	3.6	45

#	Article	IF	Citations
271	Mechanism and Effects of Glucose Absorption during an Oral Glucose Tolerance Test Among Females and Males. Journal of Clinical Endocrinology and Metabolism, 2011, 96, 515-524.	3.6	92
272	Gastric Bypass Surgery Enhances Glucagon-Like Peptide 1â€“Stimulated Postprandial Insulin Secretion in Humans. Diabetes, 2011, 60, 2308-2314.	0.6	294
273	Liver Enzymes Are Associated With Hepatic Insulin Resistance, Insulin Secretion, and Glucagon Concentration in Healthy Men and Women. Diabetes, 2011, 60, 1660-1667.	0.6	112
274	Genetic variation in PNPLA3 (adiponutrin) confers sensitivity to weight lossâ€“induced decrease in liver fat in humans. American Journal of Clinical Nutrition, 2011, 94, 104-111.	4.7	131
275	Coordinated Defects in Hepatic Long Chain Fatty Acid Metabolism and Triglyceride Accumulation Contribute to Insulin Resistance in Non-Human Primates. PLoS ONE, 2011, 6, e27617.	2.5	33
276	Impact of Tobacco Smoking on Lipid Metabolism, Body Weight and Cardiometabolic Risk. Current Pharmaceutical Design, 2010, 16, 2526-2530.	1.9	32
277	Metabolic effects of soy supplementation in postmenopausal Caucasian and African American women: a randomized, placebo-controlled trial. American Journal of Obstetrics and Gynecology, 2010, 203, 153.e1-153.e9.	1.3	55
278	Pioglitazone in the treatment of NASH: the role of adiponectin. Alimentary Pharmacology and Therapeutics, 2010, 32, 769-775.	3.7	97
279	ORIGINAL ARTICLE: Pioglitazone improvement of fasting and postprandial hyperglycaemia in Mexicanâ€American patients with Type 2 diabetes: a double tracer OGTT study. Clinical Endocrinology, 2010, 73, 339-345.	2.4	13
280	Acute effects of gastric bypass versus gastric restrictive surgery on Î²-cell function and insulinotropic hormones in severely obese patients with type 2 diabetes. International Journal of Obesity, 2010, 34, 462-471.	3.4	242
281	Effect of Oral Sebacic Acid on Postprandial Glycemia, Insulinemia, and Glucose Rate of Appearance in Type 2 Diabetes. Diabetes Care, 2010, 33, 2327-2332.	8.6	24
282	Insulin resistance, adipose depots and gut: Interactions and pathological implications. Digestive and Liver Disease, 2010, 42, 310-319.	0.9	27
283	Fatty liver disease: the hepatic manifestation of metabolic syndrome. Hypertension Research, 2010, 33, 546-547.	2.7	33
284	Ectopic fat and cardiovascular disease: What is the link?. Nutrition, Metabolism and Cardiovascular Diseases, 2010, 20, 481-490.	2.6	139
285	82 KRUPPEL LIKE FACTOR 6 (KLF6) REGULATES HEAPTIC INSULIN RESISTANCE (HEP-IR). Journal of Hepatology, 2010, 52, S37.	3.7	0
286	340 FATTY LIVER INDEX (FLI) IS AN INDEPENDENT PREDICTOR OF CHANGES IN METABOLIC AND CARDIOVASCULAR PARAMETERS: RESULTS FROM A 3-YEAR FOLLOW UP IN THE RISC STUDY. Journal of Hepatology, 2010, 52, S142.	3.7	0
287	The L-4F mimetic peptide prevents insulin resistance through increased levels of HO-1, pAMPK, and pAKT in obese mice. Journal of Lipid Research, 2009, 50, 1293-1304.	4.2	100
288	Decreased whole body lipolysis as a mechanism of the lipid-lowering effect of pioglitazone in type 2 diabetic patients. American Journal of Physiology - Endocrinology and Metabolism, 2009, 297, E225-E230.	3.5	27

#	Article	IF	Citations
289	Improved tolerance to sequential glucose loading (Staub-Traugott effect): size and mechanisms. American Journal of Physiology - Endocrinology and Metabolism, 2009, 297, E532-E537.	3.5	74
290	Fasting insulin has a stronger association with an adverse cardiometabolic risk profile than insulin resistance: the RISC study. European Journal of Endocrinology, 2009, 161, 223-230.	3.7	20
291	Heme Oxygenase-1 Induction Remodels Adipose Tissue and Improves Insulin Sensitivity in Obesity-Induced Diabetic Rats. Hypertension, 2009, 53, 508-515.	2.7	160
292	Pancreatic islet amyloidosis, Î²-cell apoptosis, and Î±-cell proliferation are determinants of islet remodeling in type-2 diabetic baboons. Proceedings of the National Academy of Sciences of the United States of America, 2009, 106, 13992-13997.	7.1	147
293	Fatty liver is associated with insulin resistance, risk of coronary heart disease, and early atherosclerosis in a large European population. Hepatology, 2009, 49, 1537-1544.	7.3	310
294	Sites and mechanisms of insulin resistance in nonobese, nondiabetic patients with chronic hepatitis C. Hepatology, 2009, 50, 697-706.	7.3	140
295	Importance of changes in adipose tissue insulin resistance to histological response during thiazolidinedione treatment of patients with nonalcoholic steatohepatitis. Hepatology, 2009, 50, 1087-1093.	7.3	231
296	Reply:. Hepatology, 2009, 50, 989-990.	7.3	0
297	Accurate segmentation of subcutaneous and intermuscular adipose tissue from MR images of the thigh. Journal of Magnetic Resonance Imaging, 2009, 29, 677-684.	3.4	79
298	Elevated Concentrations of Liver Enzymes and Ferritin Identify a New Phenotype of Insulin Resistance: Effect of Weight Loss After Gastric Banding. Obesity Surgery, 2009, 19, 80-86.	2.1	21
299	Predictive models of insulin resistance derived from simple morphometric and biochemical indices related to obesity and the metabolic syndrome in baboons. Cardiovascular Diabetology, 2009, 8, 22.	6.8	34
300	A new approach to study in vivo cellular metabolism using a modellistic analysis of magnetic resonance spectra. Mathematical Biosciences, 2009, 222, 36-41.	1.9	2
301	Hepatic fat is not associated with Î²-cell function or postprandial free fatty acid response. Metabolism: Clinical and Experimental, 2009, 58, 196-203.	3.4	21
302	The Effect of Menopause on Carotid Artery Remodeling, Insulin Sensitivity, and Plasma Adiponectin in Healthy Women. American Journal of Hypertension, 2009, 22, 364-370.	2.0	44
303	55 METABOLIC AND ANTI-INFLAMMATORY BENEFICIAL EFFECTS OF PIOGLITAZONE (PIO) TREATMENT IN PATIENTS WITH NON-ALCOHOLIC STEATOHEPATITIS (NASH) AND THEIR ASSOCIATIONS WITH HISTOLOGICAL IMPROVEMENT. Journal of Hepatology, 2009, 50, S24.	3.7	1
304	346 INCREASED LIVER EXPRESSION OF INFLAMMATORY MEDIATORS IS ASSOCIATED WITH HEPATIC INSULIN RESISTANCE IN LEAN, NON-DIABETIC PATIENTS WITH CHRONIC HEPATITIS C. Journal of Hepatology, 2009, 50, S133.	3.7	0
305	Imaging and Laboratory Biomarkers in Cardiovascular Disease. Current Pharmaceutical Design, 2009, 15, 1131-1141.	1.9	9
306	Behavior therapy for nonalcoholic fatty liver disease: The need for a multidisciplinary approach. Hepatology, 2008, 47, 746-754.	7.3	204

#	Article	IF	Citations
307	Loss of 50% of excess weight using a very low energy diet improves insulin-stimulated glucose disposal and skeletal muscle insulin signalling in obese insulin-treated type 2 diabetic patients. Diabetologia, 2008, 51, 309-319.	6.3	63
308	Automatic correction of intensity inhomogeneities improves unsupervised assessment of abdominal fat by MRI. Journal of Magnetic Resonance Imaging, 2008, 28, 403-410.	3.4	29
309	Model-based assessment of insulin sensitivity of glucose disposal and endogenous glucose production from double-tracer oral glucose tolerance test. Computer Methods and Programs in Biomedicine, 2008, 89, 132-140.	4.7	17
310	Molecular basis and mechanisms of progression of non-alcoholic steatohepatitis. Trends in Molecular Medicine, 2008, 14, 72-81.	6.7	381
311	36 FATTY LIVER INDEX IS ASSOCIATED WITH INCREASED INSULIN RESISTANCE AND CAROTID INTIMA MEDIA THICKNESS (IMT) IN NONDIABETIC SUBJECTS: THE RISC STUDY. Journal of Hepatology, 2008, 48, S16.	3.7	0
312	Variation in the ADIPOQ gene promoter is associated with carotid intima media thickness independent of plasma adiponectin levels in healthy subjects. European Heart Journal, 2008, 29, 386-393.	2.2	45
313	Separate Impact of Obesity and Glucose Tolerance on the Incretin Effect in Normal Subjects and Type 2 Diabetic Patients. Diabetes, 2008, 57, 1340-1348.	0.6	353
314	Early Hypertension Is Associated With Reduced Regional Cardiac Function, Insulin Resistance, Epicardial, and Visceral Fat. Hypertension, 2008, 51, 282-288.	2.7	107
315	The Crosstalk Between Insulin and Renin-Angiotensin-Aldosterone Signaling Systems and its Effect on Glucose Metabolism and Diabetes Prevention. Current Vascular Pharmacology, 2008, 6, 301-312.	1.7	76
316	Intra-abdominal adiposity, abdominal obesity, and cardiometabolic risk. Country Review Ukraine, 2008, 10, B4-B10.	0.8	30
317	Abdominal fat: does it predict the development of type 2 diabetes?. American Journal of Clinical Nutrition, 2008, 87, 1118-1119.	4.7	22
318	Thiazolidinediones improve Î²-cell function in type 2 diabetic patients. American Journal of Physiology - Endocrinology and Metabolism, 2007, 292, E871-E883.	3.5	167
319	Insulin Resistance, Insulin Response, and Obesity as Indicators of Metabolic Risk. Journal of Clinical Endocrinology and Metabolism, 2007, 92, 2885-2892.	3.6	149
320	Effects on insulin secretion and insulin action of a 48-h reduction of plasma free fatty acids with acipimox in nondiabetic subjects genetically predisposed to type 2 diabetes. American Journal of Physiology - Endocrinology and Metabolism, 2007, 292, E1775-E1781.	3.5	89
321	Effect of a daily supplement of soy protein on body composition and insulin secretion in postmenopausal women. Fertility and Sterility, 2007, 88, 1609-1617.	1.0	64
322	Pioglitazone treatment increases whole body fat but not total body water in patients with non-alcoholic steatohepatitis. Journal of Hepatology, 2007, 47, 565-570.	3.7	73
323	Impaired myocardial metabolic reserve and substrate selection flexibility during stress in patients with idiopathic dilated cardiomyopathy. American Journal of Physiology - Heart and Circulatory Physiology, 2007, 293, H3270-H3278.	3.2	169
324	Quantification of Liver Glucose Metabolism by Positron Emission Tomography: Validation Study in Pigs. Gastroenterology, 2007, 132, 531-542.	1.3	61

#	Article	IF	Citations
325	Relationship Between Hepatic/Visceral Fat and Hepatic Insulin Resistance in Nondiabetic and Type 2 Diabetic Subjects. Gastroenterology, 2007, 133, 496-506.	1.3	500
326	Effect of Pioglitazone on the Metabolic and Hormonal Response to a Mixed Meal in Type II Diabetes. Clinical Pharmacology and Therapeutics, 2007, 81, 205-212.	4.7	58
327	Reduction in Hematocrit and Hemoglobin Following Pioglitazone Treatment is not Hemodilutional in Type II Diabetes Mellitus. Clinical Pharmacology and Therapeutics, 2007, 82, 275-281.	4.7	80
328	Early-onset type 2 diabetes in obese white subjects is characterised by a marked defect in beta cell insulin secretion, severe insulin resistance and a lack of response to aerobic exercise training. Diabetologia, 2007, 50, 1500-1508.	6.3	76
329	A Placebo-Controlled Trial of Pioglitazone in Subjects with Nonalcoholic Steatohepatitis. New England Journal of Medicine, 2006, 355, 2297-2307.	27.0	1,584
330	O-210. Fertility and Sterility, 2006, 86, S90.	1.0	0
331	[11C]palmitate kinetics across the splanchnic bed in arterial, portal and hepatic venous plasma during fasting and euglycemic hyperinsulinemia. Nuclear Medicine and Biology, 2006, 33, 521-528.	0.6	18
332	Pathogenesis and Clinical Features of Obesity and Insulin Resistance. Immunology, Endocrine and Metabolic Agents in Medicinal Chemistry, 2006, 6, 81-89.	0.5	0
333	ANALYSIS OF DOUBLE-TRACER GLUCOSE KINETICS IN HUMANS DURING ORAL GLUCOSE TOLERANCE TEST. IFAC Postprint Volumes IPPV / International Federation of Automatic Control, 2006, 39, 57-62.	0.4	0
334	Reduction in hematocrit level after pioglitazone treatment is correlated with decreased plasma free testosterone level, not hemodilution, in women with polycystic ovary syndrome. Clinical Pharmacology and Therapeutics, 2006, 80, 105-114.	4.7	26
335	Circulating Soluble Receptor for Advanced Glycation End Products Is Inversely Associated with Glycemic Control and S100A12 Protein. Journal of Clinical Endocrinology and Metabolism, 2006, 91, 4628-4634.	3.6	204
336	The Effect of Rosiglitazone on the Liver: Decreased Gluconeogenesis in Patients with Type 2 Diabetes. Journal of Clinical Endocrinology and Metabolism, 2006, 91, 806-812.	3.6	64
337	The Effect of Pioglitazone on the Liver: Role of adiponectin. Diabetes Care, 2006, 29, 2275-2281.	8.6	76
338	Comparison of Glargine Insulin Versus Rosiglitazone Addition in Poorly Controlled Type 2 Diabetic Patients on Metformin Plus Sulfonylurea. Diabetes Care, 2006, 29, 2371-2377.	8.6	26
339	18F-FDG assessment of glucose disposal and production rates during fasting and insulin stimulation: a validation study. Journal of Nuclear Medicine, 2006, 47, 1016-22.	5.0	33
340	Insulin resistance in non-diabetic patients with non-alcoholic fatty liver disease: sites and mechanisms. Diabetologia, 2005, 48, 634-642.	6.3	642
341	Visceral fat and beta cell function in non-diabetic humans. Diabetologia, 2005, 48, 2090-2096.	6.3	49
342	Characterization of Î²-cell function impairment in first-degree relatives of type 2 diabetic subjects: modeling analysis of 24-h triple-meal tests. American Journal of Physiology - Endocrinology and Metabolism, 2005, 288, E541-E546.	3.5	24

#	Article	IF	Citations
343	Î²-Cell Function in Subjects Spanning the Range from Normal Glucose Tolerance to Overt Diabetes: A New Analysis. Journal of Clinical Endocrinology and Metabolism, 2005, 90, 493-500.	3.6	470
344	Plasma Adiponectin in Nonalcoholic Fatty Liver Is Related to Hepatic Insulin Resistance and Hepatic Fat Content, Not to Liver Disease Severity. Journal of Clinical Endocrinology and Metabolism, 2005, 90, 3498-3504.	3.6	370
345	Â-Cell Function in Morbidly Obese Subjects During Free Living: Long-Term Effects of Weight Loss. Diabetes, 2005, 54, 2382-2389.	0.6	88
346	Â-Cell Function in Mild Type 2 Diabetic Patients: Effects of 6-month glucose lowering with nateglinide. Diabetes Care, 2005, 28, 1132-1138.	8.6	25
347	Separate Contribution of Diabetes, Total Fat Mass, and Fat Topography to Glucose Production, Gluconeogenesis, and Glycogenolysis. Journal of Clinical Endocrinology and Metabolism, 2004, 89, 3914-3921.	3.6	103
348	Visceral Fat in Hypertension. Hypertension, 2004, 44, 127-133.	2.7	239
349	Vascular Effects of Improving Metabolic Control With Metformin or Rosiglitazone in Type 2 Diabetes. Diabetes Care, 2004, 27, 1349-1357.	8.6	170
350	Beta-Cell Function in Obesity: Effects of Weight Loss. Diabetes, 2004, 53, S26-S33.	0.6	114
351	Beta-cell dysfunction and glucose intolerance: results from the San Antonio metabolism (SAM) study. Diabetologia, 2004, 47, 31-39.	6.3	287
352	re: Gastaldelli A, Ferrannini E, Miyazaki Y, Matsuda M, DeFronzo RA (2004) Beta cell dysfunction and glucose intolerance: results from the San Antonio metabolism (SAM) study. Diabetologia 47:31?39. Diabetologia, 2004, 47, 1642-1643.	6.3	3
353	Reply to Comment on: Gastaldelli A, Ferrannini E, Miyazaki Y, Matsuda M, DeFronzo RA (2004) Beta cell dysfunction and glucose intolerance: results from the San Antonio metabolism (SAM) study. Diabetologia 43:31?39. Diabetologia, 2004, 47, 1643-1644.	6.3	6
354	An accurate and robust method for unsupervised assessment of abdominal fat by MRI. Journal of Magnetic Resonance Imaging, 2004, 20, 684-689.	3.4	140
355	60 Metabolic significance of hepatic steatosis in non alcoholic fatty liver disease and HCV chronic hepatitis. Journal of Hepatology, 2004, 40, 21.	3.7	1
356	Predominant role of reduced beta-cell sensitivity to glucose over insulin resistance in impaired glucose tolerance. Diabetologia, 2003, 46, 1211-1219.	6.3	103
357	A Sustained Increase in Plasma Free Fatty Acids Impairs Insulin Secretion in Nondiabetic Subjects Genetically Predisposed to Develop Type 2 Diabetes. Diabetes, 2003, 52, 2461-2474.	0.6	447
358	Influence of Ethnicity and Familial Diabetes on Glucose Tolerance and Insulin Action: A Physiological Analysis. Journal of Clinical Endocrinology and Metabolism, 2003, 88, 3251-3257.	3.6	39
359	Effect of Acute Hyperglycemia on Insulin Secretion in Humans. Diabetes, 2002, 51, S130-S133.	0.6	77
360	Metabolic Effects of Visceral Fat Accumulation in Type 2 Diabetes. Journal of Clinical Endocrinology and Metabolism, 2002, 87, 5098-5103.	3.6	236

#	Article	IF	Citations
361	Meal and oral glucose tests for assessment of Î²-cell function: modeling analysis in normal subjects. American Journal of Physiology - Endocrinology and Metabolism, 2002, 283, E1159-E1166.	3.5	267
362	Assessing Insulin Secretion by Modeling in Multiple-Meal Tests: Role of Potentiation. Diabetes, 2002, 51, S221-S226.	0.6	209
363	A model for glucose control of insulin secretion during 24 h of free living. Diabetes, 2001, 50, S164-S168.	0.6	53
364	A model for assessing insulin secretion and its control under free-living conditions. Diabetes, 2001, 50, S178-S179.	0.6	5
365	Determination of the Enrichment of the Hydrogen Bound to Carbon 5 of Glucose on 2H2O Administration. Analytical Biochemistry, 2001, 297, 195-197.	2.4	35
366	Effect of Physiological Hyperinsulinemia on Gluconeogenesis in Nondiabetic Subjects and in Type 2 Diabetic Patients. Diabetes, 2001, 50, 1807-1812.	0.6	136
367	Hyperinsulinemia and Autonomic Nervous System Dysfunction in Obesity. Circulation, 2001, 103, 513-519.	1.6	209
368	A Model for Assessing Insulin Secretion Function During a 24 Hour Standardized Life Period. IFAC Postprint Volumes IPPV / International Federation of Automatic Control, 2000, 33, 35-40.	0.4	0
369	Determinants of postabsorptive endogenous glucose output in non-diabetic subjects. Diabetologia, 2000, 43, 1266-1272.	6.3	48
370	Dose-response characteristics of insulin action on glucose metabolism: a non-steady-state approach. American Journal of Physiology - Endocrinology and Metabolism, 2000, 278, E794-E801.	3.5	82
371	Insulin prolongs the QTc interval in humans. American Journal of Physiology - Regulatory Integrative and Comparative Physiology, 2000, 279, R2022-R2025.	1.8	70
372	Fat metabolism during high-intensity exercise in endurance-trained and untrained men. Metabolism: Clinical and Experimental, 2000, 49, 122-128.	3.4	87
373	Influence of obesity and type 2 diabetes on gluconeogenesis and glucose output in humans: a quantitative study. Diabetes, 2000, 49, 1367-1373.	0.6	285
374	Modelling Interpretation of the Kinetics of Metabolic Processes. , 2000, , 305-328.		0
375	Assessment of methods for improving tracer estimation of non-steady-state rate of appearance. Journal of Applied Physiology, 1999, 87, 1813-1822.	2.5	58
376	Triglyceride-induced diabetes associated with familial lipoprotein lipase deficiency. Diabetes, 1999, 48, 1258-1263.	0.6	96
377	Insulin: new roles for an ancient hormone. European Journal of Clinical Investigation, 1999, 29, 842-852.	3.4	114
378	Linear and Nonlinear Properties of Heart Rate Variability: Influence of Obesity. Annals of the New York Academy of Sciences, 1999, 879, 249-254.	3.8	5

#	Article	IF	Citations
379	A modellistic view of the kinetics of metabolic processes: differences in the glucose and xylose degradation pathway. Chemical Physics Letters, 1999, 310, 38-42.	2.6	7
380	Splanchnic and leg substrate exchange after ingestion of a natural mixed meal in humans. Diabetes, 1999, 48, 958-966.	0.6	78
381	Influence of duration of obesity on the insulin resistance of obese non-diabetic patients. International Journal of Obesity, 1998, 22, 262-267.	3.4	39
382	Autonomic and Hemodynamic Responses to Insulin in Lean and Obese Humans¹. Journal of Clinical Endocrinology and Metabolism, 1998, 83, 2084-2090.	3.6	105
383	Effects of acute Î±₂-blockade on insulin action and secretion in humans. American Journal of Physiology - Endocrinology and Metabolism, 1998, 274, E57-E64.	3.5	10
384	Autonomic and Hemodynamic Responses to Insulin in Lean and Obese Humans. Journal of Clinical Endocrinology and Metabolism, 1998, 83, 2084-2090.	3.6	90
385	Glucose kinetics in interstitial fluid can be predicted by compartmental modeling. American Journal of Physiology - Endocrinology and Metabolism, 1997, 272, E494-E505.	3.5	11
386	Regulation of glucose production during exercise at 80% of VO2peak in untrained humans. American Journal of Physiology - Endocrinology and Metabolism, 1997, 273, E348-E354.	3.5	13
387	Regulation of plasma fatty acid oxidation during low- and high-intensity exercise. American Journal of Physiology - Endocrinology and Metabolism, 1997, 272, E1065-E1070.	3.5	69
388	Effects of troglitazone on insulin action and cardiovascular risk factors in patients with non-insulin-dependent diabetes. Clinical Pharmacology and Therapeutics, 1997, 62, 194-202.	4.7	47
389	Energy expenditure of swimmers during high volume training. Medicine and Science in Sports and Exercise, 1997, 29, 950-954.	0.4	60
390	Kinetic Analysis and Comparison of Models of Xylose Metabolism byKlebsiella planticola. Biochemical and Biophysical Research Communications, 1996, 227, 41-46.	2.1	10
391	Modeling Interpretation of Microbe Metabolism Detected by Nuclear Magnetic Resonance. Biochemical and Biophysical Research Communications, 1996, 227, 53-58.	2.1	10
392	Effect of theophylline on substrate metabolism during exercise. Metabolism: Clinical and Experimental, 1996, 45, 1153-1160.	3.4	42
393	A new correction factor for use in tracer estimations of plasma fatty acid oxidation. American Journal of Physiology - Endocrinology and Metabolism, 1995, 269, E649-E656.	3.5	122
394	Glucose kinetics during high-intensity exercise in endurance-trained and untrained humans. Journal of Applied Physiology, 1995, 78, 1203-1207.	2.5	66
395	Lipid and Carbohydrate Metabolism in IDDM During Moderate and Intense Exercise. Diabetes, 1995, 44, 1066-1074.	0.6	42
396	Pathway of free fatty acid oxidation in human subjects. Implications for tracer studies.. Journal of Clinical Investigation, 1995, 95, 278-284.	8.2	82

#	Article	IF	Citations
397	Lipid and carbohydrate metabolism in IDDM during moderate and intense exercise. Diabetes, 1995, 44, 1066-1074.	0.6	12
398	Protein synthesis and breakdown in skin and muscle: a leg model of amino acid kinetics. American Journal of Physiology - Endocrinology and Metabolism, 1994, 267, E467-E474.	3.5	47
399	Validation of Tracer Estimations of Plasma Free Fatty Acid Oxidation. Clinical Science, 1994, 87, 94-95.	0.0	0
400	Changes in Tracer Infusion Rates to Minimize the Structure Error in the Steeleâ€™s Model. IFAC Postprint Volumes IPPV / International Federation of Automatic Control, 1994, 27, 281-282.	0.4	0
401	An Energy Model for the Description of a Metabolic Process. IFAC Postprint Volumes IPPV / International Federation of Automatic Control, 1994, 27, 377-378.	0.4	0
402	A Leg Model of Amino Acid Kinetics in Skin and Muscle. IFAC Postprint Volumes IPPV / International Federation of Automatic Control, 1994, 27, 391-393.	0.4	0
403	Pathway of Free Fatty Acid Oxidation. IFAC Postprint Volumes IPPV / International Federation of Automatic Control, 1994, 27, 413-414.	0.4	0
404	850 PATHWAY OF PLASMA FFA OXIDATION DURING EXERCISE. Medicine and Science in Sports and Exercise, 1994, 26, S152.	0.4	0
405	Regulation of endogenous fat and carbohydrate metabolism in relation to exercise intensity and duration. American Journal of Physiology - Endocrinology and Metabolism, 1993, 265, E380-E391.	3.5	956
406	Assessment of RANKL/RANK/osteoprotegerin system expression in patients with hepatocellular carcinoma. Minerva Endocrinology, 0, , .	1.1	3
407	Reduced insulin clearance relates to increased liver fat content in recent-onset type 2 diabetes and to impaired glucose control in recent-onset type 1 diabetes. Endocrine Abstracts, 0, , .	0.0	0